Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IDEAYA BIOSCIENCES, INC.

(IDYA)
  Report
Delayed Nasdaq  -  04:00 2022-12-05 pm EST
17.77 USD   -1.17%
12/05IDEAYA Biosciences Gets FDA OK to Fast-Track Melanoma Treatment
DJ
12/05IDEAYA Biosciences Gets FDA Fast Track Designation for Combination Therapy Targeting Metastatic Uveal Melanoma
MT
12/05IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2022 11/30/2022 12/01/2022 12/02/2022 12/05/2022 Date
17.19(c) 17.88(c) 17.77(c) 17.98(c) 17.77(c) Last
306 081 732 642 339 229 421 859 327 865 Volume
+3.99% +4.01% -0.62% +1.18% -1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 53,5 M - -
Net income 2022 -59,5 M - -
Net cash position 2022 373 M - -
P/E ratio 2022 -12,0x
Yield 2022 -
Sales 2023 16,9 M - -
Net income 2023 -122 M - -
Net cash position 2023 268 M - -
P/E ratio 2023 -6,79x
Yield 2023 -
Capitalization 865 M 865 M -
EV / Sales 2022 9,20x
EV / Sales 2023 35,3x
Nbr of Employees 95
Free-Float 98,2%
More Financials
Company
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The Company is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having... 
Sector
Biotechnology & Medical Research
Calendar
12/12 | 08:00amR&D Day
More about the company
Ratings of IDEAYA Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about IDEAYA BIOSCIENCES, INC.
12/05IDEAYA Biosciences Gets FDA OK to Fast-Track Melanoma Treatment
DJ
12/05IDEAYA Biosciences Gets FDA Fast Track Designation for Combination Therapy Targeting Me..
MT
12/05IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy..
PR
11/29IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Invest..
PR
11/28IDEAYA Biosciences Names Darrin Beaupre Chief Medical Officer
MT
11/28IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to..
PR
11/28IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Cl..
CI
11/18Baird Raises Price Target on IDEAYA Biosciences to $24 From $18, Maintains Outperform R..
MT
11/14Certain Common Stock of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement End..
CI
11/14Certain Stock Options of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement En..
CI
11/09IDEAYA Biosciences Inc. Reports Third Quarter 2022 Financial Results and Provides Busin..
AQ
11/08IDEAYA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/08IDEAYA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/08IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Busi..
PR
11/01IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming I..
PR
More news
News in other languages on IDEAYA BIOSCIENCES, INC.
11/28IDEAYA Biosciences, Inc. nomme Darrin M. Beaupre au poste de Directeur médical en chef ..
11/08IDEAYA Biosciences, Inc. annonce ses résultats financiers pour le troisième trimestre e..
10/18IDEAYA Biosciences, Inc. annonce que l'inhibiteur de MAT2A de phase 2, IDE397, obtient ..
09/15Mise à jour sectorielle : Les actions du secteur de la santé son..
09/15IDEAYA Biosciences lance une offre d'actions ordinaires pour un montant de 80 millions ..
More news
Analyst Recommendations on IDEAYA BIOSCIENCES, INC.
More recommendations
ETFs positioned on IDEAYA BIOSCIENCES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.77%4.61%United_States
ALPS Medical Breakthroughs ETF - USD0.33%4.65%United_States
SPDR S&P Biotech ETF - USD0.25%5.67%United_States
ETFs S&P Biotech ETF - Distributing - AUD0.25%4.18%-United_States
IShares Micro-Cap ETF - USD0.12%1.43%United_States
More ETFs positioned on IDEAYA BIOSCIENCES, INC.
Chart IDEAYA BIOSCIENCES, INC.
Duration : Period :
IDEAYA Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDEAYA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 17,77 $
Average target price 24,13 $
Spread / Average Target 35,8%
EPS Revisions
Managers and Directors
Yujiro S. Hata President, Chief Executive Officer & Director
Paul A. Stone Chief Financial Officer & Executive Vice President
Timothy M. Shannon Chairman
Matthew Maurer VP, Head-Medical Affairs & Clinical Oncology
Michael Anthony White Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
IDEAYA BIOSCIENCES, INC.-23.94%865
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-21.59%22 727